Antinociceptive Properties of Labetalol in the Rat Formalin Test

Davidson, Morris; Szmuk, Peter; Doursout, Marie–Françoise; Chelly, Jacques E.

doi:10.1097/00000542-199809190-00020

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…102 103 Esmolol also decreases nociception in a variety of experimental settings, suggesting the potential to decrease the intraoperative anaesthetic requirements. 47 Altered distribution and decreased metabolism of opioids by b-AAs may underlie this anaesthetic-sparing effect. 182 Furthermore, although b-AAs per se do not provide analgesia or hypnosis, they are known to have central nervous system modulating activities and anxiolytic effects.…”

Section: Non-cardiac Considerationsmentioning

confidence: 99%

“…15 181 Notably, pure b-adrenergic antagonism is crucial for the observed anaesthetic-sparing effect because labetalol increases the anaesthetic requirement. 47 Even though esmolol and atenolol are hydrophilic b-AAs, they produce the same plasma/cerebrospinal¯uid ratio as lipophilic b-AAs, thereby affecting the centrally located surface b-ARs. 120 Another mechanism that may signi®cantly contribute to the anaesthetic-sparing effect elicited by b-AAs involves decreased excitatory stimulation of central nervous effector sites of hypnosis and somatic response.…”

Section: Non-cardiac Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Modulation of β-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action

Zaugg

Schaub

Pasch

et al. 2002

British Journal of Anaesthesia

View full text Add to dashboard Cite

This review focuses on the mechanisms and sites of action underlying beta-adrenergic antagonism in perioperative medicine. A large body of knowledge has recently emerged from basic and clinical research concerning the mechanisms of the life-saving effects of beta-adrenergic antagonists (beta-AAs) in high-risk cardiac patients. This article re-emphasizes the mechanisms underlying beta-adrenergic antagonism and also illuminates novel rationales behind the use of perioperative beta-AAs from a biological point of view. Particularly, it delineates new concepts of beta-adrenergic signal transduction emerging from transgenic animal models. The role of the different characteristics of various beta-AAs is discussed, and evidence will be presented for the selection of one specific agent over another on the basis of individual drug profiles in defined clinical situations. The salutary effects of beta-AAs on the cardiovascular system will be described at the cellular and molecular levels. Beta-AAs exhibit many effects beyond a reduction in heart rate, which are less known by perioperative physicians but equally desirable in the perioperative care of high-risk cardiac patients. These include effects on core components of an anaesthetic regimen, such as analgesia, hypnosis, and memory function. Despite overwhelming evidence of benefit, beta-AAs are currently under-utilized in the perioperative period because of concerns of potential adverse effects and toxicity. The effects of acute administration of beta-AAs on cardiac function in the compromised patient and strategies to counteract potential adverse effects will be discussed in detail. This may help to overcome barriers to the initiation of perioperative treatment with beta-AAs in a larger number of high-risk cardiac patients undergoing surgery.

show abstract

Section: Non-cardiac Considerationsmentioning

confidence: 99%

Section: Non-cardiac Considerationsmentioning

confidence: 99%